TrialBritish journal of cancer2005

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours.

A Awada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.